Are investigations anxiolytic or anxiogenic? A randomised controlled trial of neuroimaging to provide reassurance in chronic daily headache

L Howard, S Wessely, M Leese, L Page, P McCrone, K Husain, J Tong, A Dowson

OBJECTIVES: Aims were to investigate (a) whether neuroimaging in patients with chronic daily headache reassures patients or fails to reassure them and/or worsens outcome, impacting on service use, costs, health anxieties, and symptoms, and (b) whether this reassurance process occurs differentially in patients with different levels of psychological morbidity.

METHODS: Design: randomised controlled trial; setting: headache clinic in secondary care, South London; participants: 150 patients fulfilling criteria for chronic daily headache, stratified using the Hospital Anxiety and Depression Scale (HADS); intervention: treatment as usual or the offer of an MRI brain scan; main outcome measures: use of services, costs, and health anxiety.

RESULTS: Seventy six patients were randomised to the offer of a brain scan and 74 patients to treatment as usual. One hundred and thirty seven (91%) primary care case notes were examined at 1 year, 103 (69%) patients completed questionnaires at 3 months and 96 (64%) at 1 year. Sixty six (44%) patients were HADS positive (scored >11 on either subscale). Patients offered a scan were less worried about a serious cause of the headaches at 3 months (p=0.004), but this was not maintained at 1 year; other health anxiety measures did not differ by scan status. However, at 1 year HADS positive patients offered a scan cost significantly less, by £465 (95% confidence interval (CI): £1028 to £104), than such patients not offered a scan, due to lower utilisation of medical resources.

CONCLUSIONS: Neuroimaging significantly reduces costs for patients with high levels of psychiatric morbidity, possibly by changing subsequent referral patterns of the general practitioner.

MEDICAL investigations are often performed to reassure patients they have no serious organic pathology. However, the evidence available is unclear as to whether investigations are reassuring to patients with no clinical evidence of serious pathology, reducing their anxieties and symptoms, or whether they lead to increasing concerns about health and worsen disability. Several observational studies have suggested that even invasive investigations can reassure patients, but other studies have reported a high level of psychological morbidity and somatic symptoms after standard management with diagnostic tests. These conflicting results may be partly due to methodological differences or confounding factors. There is some evidence to suggest that patients with additional psychological morbidity are less likely to be reassured by investigations than other patients presenting with similar symptoms. This may be mediated through specific illness perceptions, which may differ in patients with different levels of psychological morbidity. Cognitive models of health anxiety would also predict that patients with high levels of health anxiety would not be reassured by investigations.

There have been few randomised controlled trials investigating diagnostic tests in clinical practice. We have chosen chronic headache to investigate whether tests reassure or not, since chronic headaches are common and the consensus of evidence is that neuroimaging is not routinely required on clinical grounds. However, the US Headache Consortium suggest that a brain scan could be requested to reassure the patient. Chronic headache is also associated with psychiatric morbidity. It was therefore hypothesised that patients with chronic daily headache (CDH) and low levels of psychiatric morbidity may be reassured and have a better outcome (that is, lower levels of anxiety, lower utilisation of medical resources, and less headache symptoms) when they receive a brain scan compared with patients who do not. However, patients with CDH and psychiatric disorder who receive a scan may have a worse outcome than those who do not receive a scan. We therefore aimed to investigate whether current medical practice of using neuroimaging in patients with CDH does reassure patients, as is intended, or whether it fails to reassure or worsens outcome, that is, increases service contacts and increases anxiety, depending on levels of psychological morbidity.

METHOD

Patients

The study population was consecutive English speaking patients who fulfilled criteria for CDH, that is, at least 15 days per month of headache for more than 6 months (which can include tension type headache, migraine, and secondary headache due to extensive medication consumption), presenting as new patients to the headache clinic at King’s College Hospital in London. Sixty per cent of referrals to this clinic are given diagnoses of CDH. Referrals were primarily from general practitioners (GPs) and occasionally from neurologists. Patients were excluded if there was a clinical justification for neuroimaging (with the exception of solely providing reassurance) or if there was a medical contraindication to MRI scan. All patients were asked to consent to take part in interviews and follow up questionnaires with data from primary care case notes.

Abbreviations: CDH, chronic daily headache; 95% CI, 95% confidence interval; GP, general practitioner; HADS, Hospital Anxiety and Depression Scale; HAQ, Health Anxiety Questionnaire; IPQ-R, Revised Illness Perception Questionnaire; SF36, Medical Outcome Study Short Form 36; VAS, visual analogue scale.
Intervention
Patients were randomised to receive an offer of a screening MRI scan using a sagittal localiser image followed by a double echo axial series. Computerised tomography was not offered due to the high dose of radiation involved. Letters were sent to patients by the neurologist informing them of normal scan results, as is normal practice in this clinic. Any patients who had abnormal MRI scans were seen by the neurologist and advised appropriately.

Only patients who were randomised to receive a scan were asked for consent to randomisation to neuroimaging. This is therefore an example of post randomisation consent – the Zelen design.25 We chose this because patients who were asked to consent to randomisation but not offered a scan might have felt more anxious and less reassured than they would otherwise have done. This could have biased the results and could also have been detrimental to the patients’ welfare.

The study received ethical approval from King’s Health Care local research ethics committee. A power calculation (using nQuery Advisor software, Statistical Solutions, Cork, Ireland) showed that 30 patients in four groups would be required. Two pairwise group comparisons of the effect of a scan were of interest: firstly for those with high psychological morbidity and secondly for those with low levels. We anticipated detecting a difference of at least 9 out of 100 points in “worry about health” as measured by the visual analogue scale (VAS). This sample size would give a power of 90% using a significance level of 0.05. This level of difference was based on data from those with low levels. We anticipated detecting a difference for those with high psychological morbidity and secondly for comparisons of the effect of a scan were of interest: firstly for those with high psychological morbidity and secondly for those with low levels. We anticipated detecting a difference of at least 9 out of 100 points in “worry about health” as measured by the visual analogue scale (VAS). This sample size would give a power of 90% using a significance level of 0.05. This level of difference was based on data from those with low levels. We anticipated detecting a difference for those with high psychological morbidity and secondly for

Procedures
Randomisation based on random permuted blocks was carried out by an independent statistician (ML). A stratified procedure was used, so that patients identified as having a possible psychiatric disorder (detected by the Hospital Anxiety and Depression Scale (HADS) using a cut off of 11 for possible cases) were randomised separately.

Recruitment, consent, and baseline questionnaires were administered and took 20–30 min to complete. Patients were then seen by the director of the headache clinic who diagnosed patients and decided whether they fulfilled the inclusion criteria. He then opened the sealed envelope already inserted by the research assistant at the back of the case notes and offered or did not offer the intervention. Clinical care continued as usual (that is, explanation of symptoms, verbal reassurance of no serious pathology, and CDH advice). All patients were given a letter providing information on CDH. Patients were not routinely offered a further appointment as care is usually passed back to the GP in the UK.

Patients completed a semi-structured interview for their medical and psychiatric history and completed the following instruments:

1. Hospital Anxiety and Depression Scale (HADS)24 – a self assessment scale for detecting anxiety and depression using 11 as a cut off point. This ensured that HADS positive patients were highly likely to be cases. Anxiety and depression are very closely correlated in the general hospital26 and in the community,26 and were therefore analysed together.

2. Visual analogue scales (VAS) of level of worry about health (0–100) and level of illness belief (0–100).

3. Likert five point scales of anxiety about underlying serious illness11 (Do you think there is something seriously wrong which is causing your headaches?: I am concerned about my health; I only think about my health when I go to the doctor for an examination; My health is a big concern in my life; I often think about my health).

4. Health Anxiety Questionnaire (HAQ)28 of 21 questions with four subscales: health, worry and preoccupation; fear of illness and death; reassurance seeking behaviour; and extent to which symptoms interfere with a person’s life.

5. Medical Outcome Study Short Form 36 (SF36)11 – a questionnaire used to measure physical and emotional outcomes and assessing: physical functioning, social functioning, role functioning due to physical problems, role limitation due to emotional problems, mental health, energy and vitality, pain, and general perception of health.

6. Revised Illness Perception Questionnaire (IPQ-R)30 – a measure of cognitive representations of illness in five scales: timeline, consequences, personal control, treatment control, and illness coherence.

7. Anxiety and Depression Scale (HADS)24 using a cut off of 11 as a cut off point. This ensured that HADS positive patients were randomised separately.

Secondary outcome measures were:

<table>
<thead>
<tr>
<th>Table 1 Baseline characteristics by offer of a scan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not offered</td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>Gender: male, n (%)</td>
</tr>
<tr>
<td>Ethnic group: white, n (%)</td>
</tr>
<tr>
<td>Employed, n (%)</td>
</tr>
<tr>
<td>Marital status: single, n (%)</td>
</tr>
<tr>
<td>Age, mean (SD)</td>
</tr>
<tr>
<td>HADS score, mean (SD)</td>
</tr>
<tr>
<td>Headache index, mean (SD)</td>
</tr>
</tbody>
</table>

In order to prospectively measure headache severity, patients were sent a headache diary 6 weeks before the consultation. This gathered information on the number of days with headache, number of hours, and the intensity of the headache. A headache index27 was calculated for each patient as follows: Headache index = (no. of hours with headache)×(intensity)/no. of days recorded.

Follow ups were carried out at 3 months and 1 year, using postal questionnaires with the instruments described above, by a second research assistant (JT) who was blind to intervention status. At 1 year, primary care case notes were examined for information on consultation rate, symptoms, further investigations, and contact with secondary and tertiary care. Data were double entered onto a relational database (Access; Microsoft) and then transferred to Stata version 7.0 (SAS, Cary, NC) for analysis.

Statistical analysis
All randomised subjects (including those who did not wish to receive a scan) who could be followed up were included in an intention to treat analysis. There were no interim analyses or stopping rules. Double sided significance tests were used. Domains with missing data were omitted from the analysis. Linear regression was used for continuous clinical outcome measures and logistic models (binary and ordered) were used for binary and ordered categorical (Likert) measures. Histograms of residuals from linear regressions were plotted
RESULTS

Patient sample

Between October 1999 and April 2001 150 patients were recruited from the headache clinic, and follow up was completed in April 2002. Figure 1 shows the trial profile. Overall 137 (91%) GP case notes were examined at 1 year, and 103 (69%) patients were followed up at 3 months and 96 (64%) at 1 year.

The majority, 116 (77%), of patients were female. Mean age was 38.1 (SD 12.4) years; 62 (41%) were single, 85 (57%) were married or cohabiting, and three (2%) were divorced or separated; and 93 (62%) were employed at the time of the initial consultation. A total of 66 (44%) patients were HADS positive, with a score >11 on either subscale, with a mean score of 15.6 (SD 7.63). There was no statistically significant difference in the proportions of HADS positive patients compared with HADS negative patients by gender (p = 0.42), ethnicity (0.29), or social class (p = 0.23). However, there was a trend for HADS positive patients to be single (p = 0.073) and they were significantly more likely to be unemployed (p = 0.007). The median duration of headache was 24 months with no significant difference for HADS groups (p = 0.38).

The randomised groups were similar in age, marital status, gender, social class, and ethnicity, but patients offered a scan were more likely to be employed (table 1). Of the scans, 97% were normal and two were abnormal: a posterior fossa arachnoid cyst and a hypothalamic signal flair, neither clinically significant.

Patients who did not respond to questionnaires at 1 year were significantly younger (mean age 34.4, SD 1.34) than responders (mean age 40.1, SD 1.35) (t = 2.74; p = 0.007). Non-responders were also more likely to receive a CT than an MRI (£286). Productivity costs were not included, although the proportion of patients receiving sick notes from GPs and the number of days off work were measured. Total costs are presented with and without inpatient costs, as the latter have a disproportionate impact on total costs.

Patient outcomes were analysed separately and results were presented in the text. This latter group of results should be regarded as exploratory since we have not made any adjustment to them for multiple testing.

Primary outcomes

Patient outcomes were analysed on an intention to treat basis. Table 2 shows the service use outcomes over 1 year following randomisation. Service use data were combined with unit costs to enable service costs to be generated. NHS data were obtained for imaging costs. The intervention costs were estimated using the unit cost of a CT scan (£119), because it was assumed that in routine practice patients would be more likely to receive a CT than an MRI (£286). Productivity costs were not included, although the proportion of patients with missing outcomes at 1 year who had valid data at 3 months could be included and vice versa, with the appropriate weight being given to cases with incomplete data. A second sensitivity analysis controlled for sex, age, marital status, and employment status. Adjusted p values presented in tables control only for baseline value and HADS status, if appropriate.
significant interaction between HADS status and the offer of a scan for total service costs (table 3). This phenomenon was mainly due to differences in inpatient costs (p = 0.073) and psychiatrist costs (p = 0.04), although after correction for multiple testing this was not significant. One third of HADS positive cases not offered a scan subsequently received a brain scan that year. Excluding inpatient costs, the estimated mean difference in total costs between HADS positive cases not offered a scan and everyone else was £105 (95% CI: £15 to £248). The mean difference including inpatient costs was £387 (95% CI: £16 to £957). The 13 missing values (five, two, zero, and six cases in the four subgroups, HADS negative/positive, not offered/offered scan) were replaced by the most extreme mean, that is, that of the HADS positive cases not offered scans (£771). This increased the mean costs to £403, £478, £771, and £391 for the four groups, respectively, that is, maintaining a marked differential. If we focus on the HADS positive cases, the estimated total cost difference between those offered and those not offered a scan was £465 (95% CI: £1028 to −£104).

Table 4 shows primary clinical outcomes at 1 year comparing patients offered a scan with those not offered a scan. There was no evidence for any overall effect at 1 year in the VAS or HAQ subscales. At 3 months, the Likert scale “Do you think there is something seriously wrong which is causing your headaches?” did decrease overall (p = 0.004, ordered logistic regression), that is, the groups offered a brain scan were reassured, but this was not maintained and there were no other differences between the two randomised groups.

Table 3 Cost of services used during year following randomisation by HADS status and offer of a scan

<table>
<thead>
<tr>
<th>Service</th>
<th>HADS negative</th>
<th>HADS positive</th>
<th>p*</th>
<th>(Interaction scan × HAD status)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Not offered</td>
<td>Offered</td>
<td>Not offered</td>
<td>Offered</td>
</tr>
<tr>
<td>Intervention</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GP</td>
<td>148 (117)</td>
<td>117 (83)</td>
<td>150 (114)</td>
<td>135 (91)</td>
</tr>
<tr>
<td>Neurologist</td>
<td>33 (77)</td>
<td>3 (17)</td>
<td>46 (82)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Psychiatrist/therapist</td>
<td>5 (24)</td>
<td>3 (20)</td>
<td>93 (242)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Out patient</td>
<td>80 (103)</td>
<td>90 (193)</td>
<td>81 (125)</td>
<td>40 (55)</td>
</tr>
<tr>
<td>Other</td>
<td>6 (19)</td>
<td>7 (25)</td>
<td>1 (4)</td>
<td>2 (12)</td>
</tr>
<tr>
<td>Imaging</td>
<td>11 (23)</td>
<td>8 (24)</td>
<td>41 (87)</td>
<td>4 (8)</td>
</tr>
<tr>
<td>Test</td>
<td>8 (22)</td>
<td>5 (17)</td>
<td>3 (4)</td>
<td>6 (10)</td>
</tr>
<tr>
<td>Inpatient care</td>
<td>61 (177)</td>
<td>118 (643)</td>
<td>352 (1121)</td>
<td>9 (47)</td>
</tr>
<tr>
<td>Total service cost</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Including inpatient costs</td>
<td>352 (363)</td>
<td>464 (713)</td>
<td>771 (1314)</td>
<td>306 (162)</td>
</tr>
<tr>
<td>Excluding inpatient costs</td>
<td>292 (257)</td>
<td>346 (220)</td>
<td>419 (367)</td>
<td>297 (137)</td>
</tr>
</tbody>
</table>

*p based on robust standard errors in linear regressions; †excluding costs of lost employment.

Figure 1 CONSORT diagram showing progress of patients through trial.
There was no evidence that the effect of offering a scan differed between the two HADS groups (table 5). The results of an analysis using both time points for the VAS and HAQ scales showed very similar results to those presented for 1 year, as did analyses controlling for age, sex, marital status, and employment status.

Of the five Likert scales (not shown in the table), only “I only think about my health when I go to the doctor for an examination” showed any trend to interaction at 1 year (p = 0.071). The HADS positive cases tended to increase (indicating more health concern) and HADS negative tended to decrease after the offer of a scan.

**Secondary outcomes**

The headache index was highly skewed, and differed markedly between the HADS positive and HADS negative cases at baseline, with median scores at 1 year for HADS positive and negative cases of 22 and 14, respectively. At 1 year, the medians for HADS positive cases reduced from 22 to 10 where a scan was offered but remained high at 20 where no scan was offered, whereas the HADS negative cases reduced among both those offered and not offered a scan, to 6 and 9, respectively. The interaction term in a regression on log transformed headache indices was borderline at p = 0.06.

For the IPQ-R scales, only the “timeline” showed any evidence for interaction (p = 0.05), and only at 3 months. The HADS positive cases had similar scores (adjusted mean difference at 3 months 1.09 (95% CI: 1.96 to 3.84) whether or not offered a scan, whereas the adjusted mean difference for HADS negative cases offered a scan compared to those not offered a scan was −2.13 (95% CI: to −4.20 to −0.06).

For the SF36 scales, there was little evidence for differences either overall or for each HADS group separately, except for energy and vitality which was higher overall in the two groups offered scans (overall adjusted difference 7.12, 95% CI: 1.96 to 12.27).

**DISCUSSION**

Our results show that neuroimaging temporarily reassures patients with CDH about the cause of their headaches at 3 months, but this effect is not sustained by the 1 year follow up. The scan also did not improve most other measures of health anxiety, illness perceptions, or quality of life. We had predicted increases in anxiety for patients with higher psychological morbidity offered a brain scan on the basis of cognitive models of anxiety; according to this model reassurance, far from reducing anxiety, would increase it. However, HADS positive patients offered a scan showed little exacerbation of health related anxiety other than more health concern on one Likert measure. Even more unexpectedly, HADS positive patients offered a scan showed little less health related anxiety other than more health concern on one Likert measure. Even more unexpectedly, HADS positive patients offered a scan showed little less health related anxiety other than more health concern on one Likert measure. Even more unexpectedly, HADS positive patients offered a scan showed little less health related anxiety other than more health concern on one Likert measure. Even more unexpectedly, HADS positive patients offered a scan showed little less health related anxiety other than more health concern on one Likert measure.
patients expect a brain scan for a referral for chronic headaches in a headache clinic. Neuroimaging therefore does not appear to be anxiogenic or anxious in patients with or without psychological morbidity but does decrease service costs in HADS positive patients in the year following a headache clinic consultation.

However, we suggest on the basis of the service contact and economics data that scanning HADS positive patients may have reassured one group, namely the referring doctors. It is not possible from this study to elucidate how the interaction between the patient and the family practitioner differed depending on whether or not a patient was scanned, but the presence of a normal scan result appears to enable the GP to manage the patient more effectively and prevent the cycle of further referrals, unnecessary investigations, and potentially inappropriate treatment. This may be because the GP is reassured or because the GP feels legally covered. This study therefore suggests that the GPs, as opposed to the patients, are being reassured by a scan. Many neurologists offer scans to patients with CDH for reassurance. There are, however, potential risks from neuroimaging including radiation exposure from a CT scan, anaphylaxis from contrast used, and oversedation of claustrophobic patients. Our study failed to provide evidence that scans are persistently reassuring; there are therefore many reasons to avoid the risks of neuroimaging for reassurance.

This trial’s methodological strengths include comparable groups after randomisation, adequacy of the sample size for the GP data and blinding procedures, use of standardised measures, and a study population from all socio-economic groups. Although the trial setting, a secondary referral headache clinic, is not a typical neurology outpatient clinic, the clinical setting used meant that there was no confounding effect of different doctors reassuring patients in different ways. The main methodological limitation was the differential follow up: non-responders may have had worse psychological outcomes than responders, although there were few baseline differences between patients who responded to questionnaires and those who did not. The response rate was lower than expected which meant there was a lack of statistical power for some of the outcome measures, although we achieved a very high level of information from GP case notes. Finally, it is difficult to measure reassurance; our measures were only able to examine some of the possible cognitions and emotions involved in reassurance. Furthermore, single items such as Likert scales may have relatively high imprecision. The HADS score may be too insensitive a measure of severity of the cause of the headache; a design that stratified patients on the basis of a specific worry about the cause of headache might have been preferable.

The main finding of this study is that addition of a scan is associated with lower service costs for patients with CDH with high levels of psychological morbidity compared with such patients not offered a scan, and patients with low psychological morbidity (with or without scan). The provision of a scan, however, made little difference to overall levels of symptoms, anxiety, and health concerns, whatever the level of psychological morbidity. The implication of this study is that most patients can be effectively reassured and do not benefit from neuroimaging.

However, in certain circumstances neuroimaging may be useful in helping the referrer to manage the patient with CDH. Neuroimaging does not increase anxiety about the cause of the headache and it may be cost effective in helping the physician manage the patients with high levels of psychological morbidity in primary care. The use of a simple screening measure for psychiatric morbidity such as the HADS can be helpful in identifying patients who are likely to need particularly careful reassurance. This study suggests that neuroimaging will not be psychologically harmful to these patients, although it may reassure GPs rather than their patients.

**Authors’ affiliations**

L Howard, M Leese, P McCrone, Health Services Research Department, Institute of Psychiatry, London, UK

S Wessely, L Page, K Hussain, J Tong, Department of Psychological Medicine, Institute of Psychiatry, London, UK

A Dawson, Headache Clinic, King’s College Hospital, London, UK

This study was funded by The Wellcome Trust, grant number GR050178A.

Competing interests: none declared

**REFERENCES**


22. Dowson AJ. Analysis of the patients attending a specialist UK headache clinic, not a typical neurology outpatient clinic.


26. Dowson AJ. Analysis of the patients attending a specialist UK headache clinic, not a typical neurology outpatient clinic.


30. Dowson AJ. Analysis of the patients attending a specialist UK headache clinic, not a typical neurology outpatient clinic.


In the years 1893 and 1896 the neuropsychiatrist Gabriel Anton (1858–1933) reported on the role of the basal ganglia in choreic movements.\(^1\) He described the case of a boy with choreoathetosis and suspected isolated changes in the corpus striatum to be the cause. Until then, theories of normal brain function were not prominent and clinical disorders were poorly described. The explanations of Otto Wagner (1870–1959) and especially by Cécile Vogt (1875–1962) at the beginning of the 20th century. Anton’s attempts were developed as a pathophysiological explanation concerning the causal relationship between changes in the striatum and the development of choreoathetosis.

**The case of Cassian H**

In 1891, Anton became an associate professor of psychiatry and neuropathology in Innsbruck. From there he reported the case of the 9 year old Cassian Huber, son of a farmer, whom he had examined in the department of psychiatry. At the age of 9 months the patient was taken ill with scarlet fever and suddenly, one week later, general hyperkinesis was evident. This early physical and mental development had not been disturbed. Anton described involuntary movements in the extremities on both sides. First, he believed it was a generalised chorea but had difficulty in distinguishing the choreiform and the typical athetotic movements. Muscle tone was normal and parasthesiae lacking. The pathological-anatomic examination after death from scarlatina only showed bilateral lesions of the striatum. In the lenticular nuclei of the putamina, the grey matter had dissolved and, in between, white matter was visible. The pyramidal tract appeared intact. He suspected the isolated lesions in the putamina to be the cause of the choreoathetosis, resulting from vascular underperfusion after an infectious disorder, perhaps with a hereditary disposition.

**The contribution to research on the functions of the basal ganglia**

Taking into consideration the clinical symptoms and the neuropathological findings in the case of Cassian H, Anton suspected the complex interaction of the basal ganglia had been disturbed. He concluded that, through the absence of inhibition of movement, the necessary preconditions for normal movements disappeared. He assumed the voluntary movements were caused by the isolated changes in the corpus striatum. Furthermore he concluded that, because of the existence of an intact pyramidal tract, an extrapyramidal tract must also exist.

Anton’s first description of the changes in the striatum was later named status marmoratus (état marbré) by Cécile Vogt, who discovered the relationship between this and the extrapyramidal movement disorders. Cécile Vogt reported several case studies portraying similarities and from this is derived the term “syndrôme du corps strié”. The status marmoratus in the striatum (Vogt’s syndrome) was considered the case of double athetosis (athetose double) in childhood. Cécile Vogt, with her husband Oskar Vogt, subdivided the basal ganglial disorders on the basis of the characteristic neuropathological lesions.\(^4\)

The neurologist Alfons Jakob (1884–1931) referred to the differences between the case of Cassian H and other patients with status marmoratus.\(^5\) In contrast to Vogt’s description, Cassian H showed normal development after birth. Later, after scarlatina in the ninth month of life, the involuntary movements were observed for the first time.

The characteristic history in the case of Cassian H supports the possibility of a post-infectious, autoimmune mechanism. On views current today, it is possible Cassian H suffered from the condition described in 1686 by Thomas Sydenham (1624–1689) and now named Sydenham’s chorea. Another early medical description of chorea was given by the Dutch physician Steven Blankaat (Stephanus Blanchardus, 1650–1704) in his Lexicon Medicum Greco-Latino-Germanicum in 1696.\(^6\)

With his work on the functions of the basal ganglia, Anton made an important contribution to the research of movement disorders.

*One of Anton’s most renowned scientific achievements was the Anton-von Bramannsche Balkenstich method. In collaboration with the surgeon Gustav von Bramann (1854–1913), he proposed a new clinical procedure for the treatment of hydrocephalus: the Balkenstich method. This operational procedure was recommended to release pressure in hydrocephalus.*

**Correspondence to:** Ekkehardt Kumbier, Department of Psychiatry and Psychotherapy, Rostock University, Germany

**E Kumbier, K Haack**

Department of Psychiatry and Psychotherapy, Rostock University, Gellherslme Straße 20, D-18147 Rostock, Germany; ekkehardt.kumbier@medizin.uni-rostock.de

Competing interests: Although Professor Didier Leyt is an associate editor of the journal the manuscript was handled by Professor Martin Rossor, editor in chief; Didier Leyt did not participate in any stage of the editorial process for this manuscript.

**References**